Amplifold

Exciva develops clinical-stage biopharmaceutical therapies focused on addressing neuropsychiatric symptoms associated with dementia, including agitation and aggression in Alzheimer’s disease. It applies a targeted drug rescue approach that identifies and repurposes previously approved or clinically tested compounds into new therapeutic candidates. Exciva conducts scientific research and clinical studies to evaluate safety and potential effectiveness of its investigational products in neuropsychiatry. Its programs include formulations and methods designed for symptomatic relief and improved behavioral outcomes. Exciva collaborates with scientific and medical professionals to advance its pipeline through regulated trial phases and regulatory processes.

Impulse Dynamics is a medical device company dedicated to offering innovative solutions for treatment of Chronic Heart Failure (CHF). The Company’s developments are based on its proprietary technology for administering Cardiac Contractility Modulation therapy. This form of treatment has been shown in European clinical trials to produce an immediate and powerful modulating effect on cardiac cells, resulting in clinically meaningful increases incardiac performance. Impulse Dynamics is spearheaded by a team of professionals including, scientists, physicians, and engineers. The Company carries out research programs in major universities and hospitals throughout the world, and is currently engaged in clinical trials in Europe and in the United States. The Optimizer with Cardiac Contractility Modulation therapy, is CE marked. See Clinical Data for more information.

Tubulis creates specialized chemotherapy drugs that target cancer and chronic illnesses by combining unique technology with disease-specific biological knowledge. This allows medical professionals to treat cancer patients with fewer side effects than traditional chemotherapy.

Atai Life Sciences is a biotechnology company that develops therapies for mental health disorders. The company focuses on creating treatments using psychedelic compounds and other methods to address conditions such as depression, anxiety, and substance use disorders. Atai collaborates with various partners and research institutions to advance its drug development pipeline, which includes several clinical-stage programs. The product portfolio includes therapies that utilize research in psychedelics and neuroscience. Atai's lead programs feature ketamine-based treatments and other compounds aimed at improving mental well-being. The company works with experts in the field to ensure the efficacy and safety of its therapies. Atai Life Sciences has received recognition for its work in mental health treatment, securing partnerships and funding to support its research initiatives. The company has been acknowledged for its contributions to psychiatry and has gained attention for its efforts to advance the understanding and treatment of mental health disorders.

Vivoryon Therapeutics, a biopharmaceutical company headquartered in Germany, is dedicated to conducting research and development as well as preclinical and clinical trials. Their primary focus is on creating therapeutic treatments for Alzheimer's disease and cancer, with pipeline products such as PQ912, PQ1565, and other PQ-family medications.

Artcline is a biotech company that creates diagnostic and therapeutic techniques for critical care medicine.

Detechgene is a biotech firm that creates a cartridge system for conducting diagnostics.

Mainz Biomed strives to be a prominent supplier of accessible diagnostic solutions for individuals worldwide. Our focus is on creating inventive products that efficiently detect the early stages of various life-threatening illnesses, such as colorectal and pancreatic cancers. For additional information about our company and our commitment to using science to preserve lives, please visit our website at www.mainzbiomed.com.

ATAI is a global biotech company builder that leverages a decentralized, technology- and data-driven platform model to serve millions of people suffering from mental health disorders. The company is committed to acquiring and efficiently developing innovative treatments that address significant unmet medical needs and lead to paradigm shifts in the mental health space. ATAI Life Sciences was founded in 2018 and is based in Munich, Bayern, Germany.

Pheiron offers a platform that is scalable, secure, and interoperable for managing health data using advanced analytics. The company's main focus is on increasing the chances of success in drug development by utilizing causal insights on targets and populations. Pheiron employs artificial intelligence to analyze various types of data related to diseases, with the goal of improving understanding and informing decisions in the drug development process. Additionally, the platform enables large-scale analysis of exome sequences to identify factors specific to sex and age in health management.

Ethris is paving a new path from genes to therapeutic proteins using our proprietary messenger RNA technology. Developed in-house, our integrated platform enables the discovery, design and development of transcript therapies that restore missing functions in patients’ cells and tissues. We will advance transcript therapies to transform the treatment of disease independently and with our partners.

SynBiotic is harnessing the healing capabilities of cannabinoids to address a range of illnesses, bringing together various resources in one place for easier access. They provide relief for conditions such as chronic pain, stress, and sleep disorders, which can greatly impact both physical and mental health.